La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Agenus a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Agenus..

Agenus (NASDAQ:AGEN) Azioni, Catena delle Opzioni

AGENUS INC

Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Inc

Agent Information Software Inc Com

Agentix Corp

On June 3, 2025, Agenus Inc. (the &quot;Company&quot;) and its wholly-owned subsidiary Agenus West, LLC (&quot;Agenus West&quot; and together with the Company, &quot;Agenus&quot;) entered into an Asset Purchase Agreement (the &quot;Purchase Agreement&quot;) with Zydus Pharmaceuticals (USA) Inc. (&quot;Zydus&quot;), a wholly owned subsidiary of Zydus Lifesciences Limited, for the sale to Zydus of substantially all of the assets comprising Agenus&#39; manufacturing operations run primarily through Agenus West (the &quot;Purchased Assets&quot;), including without limitation real estate, equipment and certain assumed contracts.
In consideration for the sale of the Purchased Assets, Zydus will pay Agenus up to $125 million, comprised of $75 million to be paid at closing (minus any amounts used by Zydus to satisfy related indebtedness at closing) and contingent payments of up to an additional $50 million that may be earned based on usage by Agenus of Zydus&#39; manufacturing business during the 36-month period following the closing.

News

Asset Sales

AGEN

Agenus Enters Into Asset Purchase Agreement With Zydus Pharmaceuticals, Sells Manufacturing Operations To Zydus Pharmaceuticals For Up To $125M

On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) U.S.-based <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45743601/zydus-to-enter-global-biologics-cdmo-business-plans-to-acquire-agenus-u-s-manufacturing-facilities" rel="noreferrer noopener">biologics CMC facilities</a>.
The acquisition marks Zydus&#8217; strategic investment in U.S.-based biologics manufacturing, thereby adding a sustainable growth driver for the group.
Agenus is a clinical-stage <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">immuno-oncology company</a>.
Zydus will acquire two biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and a contingent payment of $50 million to be paid over three years subject to the achievement of certain revenue milestones.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42216436/agenus-secures-22m-mortgage-and-announces-strategic-realignment-to-focus-on-cancer-drug-development" rel="noreferrer noopener">Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development</a>
This acquisition provides Zydus with immediate access to advanced biologics manufacturing capabilities and establishes a key presence in&nbsp;California.
As part of the transaction, Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for the clinical and commercial supply of two identified Phase-3-ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL).
Zydus will also have the first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team.
The company presented new translational data for BOT/BAL at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study demonstrated that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC).
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;We are unsurprised by the manufacturing facilities&#8217; sale and outlicensing of bot/bal as these decisions were consistent with remarks previously made by management.&#8221;
During its first-quarter earnings, Agenus said it is on track to reduce its annualized operating cash burn below $50 million starting in the second half of 2025, supported by recent cost optimization measures enabling the company to direct resources toward realizing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45344207/agenus-reports-q1-2025-financial-results-and-key-business-updates" rel="noreferrer noopener">potential of BOT/BAL</a>.
The company also mentioned it is in the final stages of an important collaboration, which will result in a substantial cash infusion.
Agenus ended the first quarter of 2025 with a consolidated cash balance of $18.5 million.
The analyst says the company has sufficient funding to advance bot/bal through a Phase 3 trial, which is expected to be initiated in the second half of 2025.
Bodnar upgraded the stock from Neutral to Buy, with <a href="https://www.benzinga.com/quote/AGEN/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $25</a>.
The analyst estimates bot/bal approval in the U.S. and EU in 2028 and 2029, respectively, with peak market penetrations of 30% in the U.S. by 2034 and 15% in the EU by 2035.
HC Wainwright estimates peak sales for bot/bal in third-line MSS-CRC of ~$929 million by 2038.
Baird maintains Agenus with a Neutral, raising the price target from $4 to $6.
Price Action: AGEN stock is up 17% at $5.86 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45768838/rivian-evs-just-got-smarter-new-app-tracks-energy-use-and-speeds-up-charging" target="_blank" rel="noreferrer noopener">Rivian EVs Just Got Smarter: New App Tracks Energy Use And Speeds Up Charging</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Upgrades

Health Care

Contracts

Analyst Ratings

Movers

Trading Ideas

General

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

WIIM

Agenus shares are trading higher after HC Wainwright & Co. and Baird raised their respective price targets on the stock.

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and raises the price target from $4 to $6.

Price Target

Baird Maintains Neutral on Agenus, Raises Price Target to $6

HC Wainwright &amp; Co. analyst Emily Bodnar upgrades Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Buy and announces $25 price target.

HC Wainwright & Co. Upgrades Agenus to Buy, Announces $25 Price Target

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares are trading higher Tuesday after the company announced it signed a partnership agreement with Zydus Lifesciences to expand patient access <a href="https://www.benzinga.com//node/45742201">to Botensilimab and Balstilimab</a>.
What To Know:&nbsp;As part of the agreement, Zydus will pay $75 million to Agenus in exchange for its biologics manufacturing assets. Agenus may also receive up to $50 million in contingent payments tied to future production orders.
Zydus will use the acquired facilities in California as its flagship U.S. sites for biologics contract manufacturing, launching a biologics contract development and manufacturing organization (BioCDMO) to serve global biopharma clients. Agenus will be Zydus' first customer under an exclusive manufacturing agreement for BOT/BAL.
In addition, Agenus will grant Zydus an exclusive license to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus receiving a 5% royalty on net sales in those regions.
As part of the collaboration, Zydus will also make a $16 million strategic equity investment in Agenus by purchasing approximately 2.1 million shares of common stock at $7.50 per share.
&#8220;We are thrilled to be partnering with Agenus to advance BOT/BAL, which has the potential to benefit thousands of patients in our core markets of India and Sri Lanka annually and millions of solid tumor patients globally. We plan to run clinical trials testing BOT/BAL in both early-stage and late-stage disease, along with expansion beyond colorectal cancer to other major disease settings like triple negative breast cancer,&#8221; said Dr. Sharvil Patel, Managing Director at Zydus Lifesciences Ltd.
See Also: <a href="https://www.benzinga.com/news/topics/25/06/45746669/jony-ive-described-by-sam-altman-as-the-greatest-designer-in-the-world-joins-openai-in-6-5b-deal-to-build-a-totally-new-kind-of-thing">Jony Ive, Described By Sam Altman As &#8216;The Greatest Designer In The World&#8217; Joins OpenAI In $6.5B Deal To Build &#8216;A Totally New Kind Of Thing&#8217;</a>
AGEN Price Action: At the time of writing, Agenus stock is trading 24.4% higher at $5.11, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjeg8j1sNWNAxU6ElkFHZRvMTEQFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro.</a>
Image: via Shutterstock

Agenus Stock Is Trading Higher Tuesday: What's Going On?

Agenus shares are trading higher after the company announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock increased by 159.9% to $4.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock moved upwards by 128.88% to $3.25. The market value of their outstanding shares is at $18.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock rose 60.82% to $1.56. The market value of their outstanding shares is at $56.4 million. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock moved upwards by 59.29% to $4.54. The market value of their outstanding shares is at $13.8 million. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) stock rose 28.75% to $5.32. The market value of their outstanding shares is at $145.7 million. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) stock increased by 21.59% to $50.05. The company's market cap stands at $3.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares fell 20.0% to $1.76 during Tuesday's pre-market session. The company's market cap stands at $25.2 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares decreased by 12.14% to $4.31. The market value of their outstanding shares is at $38.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 11.28% to $2.14. The company's market cap stands at $3.0 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 10.26% to $0.33. The market value of their outstanding shares is at $1.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) shares decreased by 8.73% to $9.95. The company's market cap stands at $15.0 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares declined by 7.51% to $0.07. The market value of their outstanding shares is at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLNN

ESLA

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MLTX

MODV

NIVF

ONCO

PRPO

PSTV

TRAW

VERO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India and Sri Lanka, capitalizing on Zydus' established local market presence and infrastructure. Zydus will pay Agenus a 5 percent royalty on net sales in those countries.</li>
<li>In a demonstration of mutual commitment, Zydus will also make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares of common stock at $7.50 per share, totaling approximately $16 million in gross proceeds. Agenus intends to apply the net proceeds from the sale of the purchased shares for working capital and general corporate purposes, and will accelerate ongoing clinical development, registration and potential commercialization of BOT/BAL.</li>
</ul>

Agenus Inks Partnership Agreement With Zydus Lifesciences To Accelerate Clinical Development, Scale Global Manufacturing, And Expand Patient Access To Botensilimab And Balstilimab For Upfront Consideration Of $75M; Agenus To Receive Up To An Additional $50M In Contingent Payments

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Shares of Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) rose sharply in today's pre-market trading following upbeat <a href="https://www.benzinga.com/quote/CRDO/news">quarterly results</a>.
The company reported fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million. The connectivity solutions company reported fourth-quarter adjusted earnings of 35 cents per share, beating analyst estimates of 28 cents per share, according to Benzinga Pro.
Credo Technology Group shares jumped 14.3% to $71.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares jumped 192.4% to $5.03 in pre-market trading. NewGenIvf Group recently announced a $30 million investment in Solana Digital Asset staking.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) surged 36.4% to $0.5878 in pre-market trading after the company announced that it will raised $13.5 million through the sale of 18 million common shares at $0.75 each to non-US investors.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) rose 36.2% to $1.12 in pre-market trading. Revelation Biosciences recently announced a $4 million public offering.</li>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) jumped 31.4% to $2.19 in pre-market trading. Eyenovia recently provided an update on its merger with Betaliq and reported better-than-expected first-quarter EPS results.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) surged 25.2% to $1.44 in pre-market trading. Northern Dynasty Minerals received payment of $12 million representing the third tranche investment under the company's royalty agreement dated July 26, 2022.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) gained 24% to $4.86 in pre-market trading after falling 35% on Monday.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) climbed 21.1% to $49.84 in pre-market trading following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.</li>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) rose 18.4% to $4.89 in pre-market trading after jumping 20% on Monday.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 8.4% to $122.62 in pre-market trading. BioNTech shares jumped 18% on Monday after the company entered into an agreement with Bristol Myers Squibb to advance bispecific antibody BNT327 for solid tumors.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares dipped 16% to $0.4119 in pre-market trading after jumping over 75% on Monday.</li>
<li>CleanCore Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#NYSE">ZONE</a>) shares fell 17.6% to $2.39 in pre-market trading after gaining around 32% on Monday.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 16.7% to $0.30 in pre-market trading.</li>
<li>ModivCare Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) fell 15% to $1.87 in pre-market trading after jumping 96% on Monday.</li>
<li>AgEagle Aerial Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>) shares tumbled 14.3% to $1.08 in pre-market trading after jumping 63% on Monday.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 14.2% to $2.25 in pre-market trading after gaining 27% on Monday.</li>
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) fell 5.9% to $2.40 in pre-market trading after jumping over 18% on Monday.</li>
<li>Bumble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NYSE">BMBL</a>) fell 5.8% to $5.41 in today's pre-market trading.</li>
<li>Pearson plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSO#NYSE">PSO</a>) dipped 5% to $15.24 in pre-market trading.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) shares fell 4.8% to $2.40 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li>W<a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">all Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

BMBL

BMGL

BNAI

BNTX

CRDO

EYEN

MREO

PSIG

REVB

SISI

SOAR

UAVS

ZONE

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket

Agenus Presents New Translational Data At ASCO 2025, Highlighting Botensilimab's Impact On MSS/pMMR Metastatic Colorectal Cancer

<ul>
<li>Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival.</li>
</ul>
Agenus Inc. ("Agenus" or the Company") (NASDAQ:<a href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activity of the combination, including durability of response and overall survival (NCT03860272).

Agenus Announces New Data From Ongoing Phase 1 Trial Evaluating BOT/BAL In Patients With MSS mCRC At 2025 ESMO Gastrointestinal Cancers Congress

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and raises the price target from $3 to $4.

Baird Maintains Neutral on Agenus, Raises Price Target to $4

<h3>Gainers</h3>
<ul>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 296.0% to $15.45 during Monday's regular session. The company's market cap stands at $92.3 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock rose 93.34% to $1.79. The market value of their outstanding shares is at $143.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares increased by 29.55% to $3.77. The market value of their outstanding shares is at $95.4 million. The company's, Q1 earnings came out today. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 25.98% to $461.12. The market value of their outstanding shares is at $6.0 billion. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) stock increased by 22.76% to $5.5. The market value of their outstanding shares is at $33.6 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 22.75% to $0.79. The market value of their outstanding shares is at $95.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares declined by 28.8% to $4.4 during Monday's regular session. The company's market cap stands at $254.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares declined by 20.0% to $0.12. The company's market cap stands at $2.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 15.02% to $0.52. The company's market cap stands at $1.1 million. </li>
<li>Apimeds Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/APUS#AMEX">APUS</a>) shares fell 13.19% to $1.91. The company's market cap stands at $24.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.18% to $0.14. The company's market cap stands at $4.0 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares declined by 10.69% to $2.92. The market value of their outstanding shares is at $15.6 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

APUS

AXDX

CTMX

IVVD

KDLY

LPCN

OMER

WORX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

Agenus shares are trading higher after the company reported better-than-expected Q1 EPS results.

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.38) by 25.36 percent. This is a 66.12 percent increase over losses of $(3.04) per share from the same period last year. The company reported quarterly sales of $24.07 million which missed the analyst consensus estimate of $26.26 million by 8.34 percent. This is a 14.07 percent decrease over sales of $28.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Agenus Q1 EPS $(1.03) Beats $(1.38) Estimate, Sales $24.07M Miss $26.26M Estimate

ACHC

ACHR

ACNT

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Press Releases

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies

Comments

Agenus

Agenus (AGEN) Opzioni

Agenus (NASDAQ:AGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO